<!doctype html><html><head><meta charset=utf-8><title>Tuberculosis, UV and perhaps vitamin D</title>
<link rel=stylesheet href="/css/main.css?v=1753303882"><link rel=stylesheet href="/css/pagination.css?v=1753303882"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src="/js/search-suggestions.js?v=1753303882"></script><script src="/js/search.js?v=1753303882"></script><script type=module>
        
        window.initPagefind = async function() {
            try {
                console.log('Loading Pagefind module...');
                window.pagefind = await import('/pagefind/pagefind.js');
                if (!window.pagefind) {
                    throw new Error('Failed to load Pagefind module - import returned empty result');
                }
                
                console.log('Initializing Pagefind...');
                const initResult = await window.pagefind.init();
                console.log('Pagefind loaded and initialized');
                
                
                if (window.searchInstance) {
                    console.log('Notifying Search instance of Pagefind initialization');
                    window.searchInstance.initializePagefind(window.pagefind);
                    console.log('Search instance successfully notified');
                } else {
                    console.warn('Search instance not found in global scope yet, but Pagefind is loaded');
                    
                }
            } catch (error) {
                console.error('CRITICAL ERROR: Failed to initialize Pagefind:', error);
                
                const errorDetails = error.stack || error.message || String(error);
                console.error('Error details:', errorDetails);
                
                
                const statusEl = document.querySelector('#search-status');
                const inputEl = document.querySelector('#search-input');
                
                if (statusEl) {
                    statusEl.textContent = 'Search unavailable: ' + error.message;
                    statusEl.style.display = 'block';
                    statusEl.style.color = 'red';
                }
                
                if (inputEl) {
                    inputEl.disabled = true;
                    inputEl.placeholder = 'Search unavailable';
                }
            }
        };
        
        
        window.pagefindInitialized = false;
        
        
        document.addEventListener('DOMContentLoaded', () => {
            console.log('DOM loaded, initializing Pagefind...');
            window.initPagefind();
        });
    </script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><div class=scroll-nav-top><a href=javascript:void(0); id=scroll-to-bottom class=scroll-button aria-label="Scroll to bottom" onclick='return window.scrollTo({top:document.body.scrollHeight,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 4a.5.5.0 01.5.5v5.793l2.146-2.147a.5.5.0 01.708.708l-3 3a.5.5.0 01-.708.0l-3-3a.5.5.0 11.708-.708L7.5 10.293V4.5A.5.5.0 018 4z"/></svg>
<span>Scroll to Bottom</span></a></div><h1>Tuberculosis, UV and perhaps vitamin D</h1><time>July 22, 2013</time><div data-pagefind-body><h1 class=svTitle><p><span style=font-size:22px>Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis</span></h1></p><div class="publicationHead titleBanner"><div class=cover><div class=title><p><a class=cLink href=http://www.sciencedirect.com/science/journal/14733099 title="Go to The Lancet Infectious Diseases on SciVerse ScienceDirect"><img alt="The Lancet Infectious Diseases" class=imgLazyJSB height=25 src=http://ars.els-cdn.com/content/image/B14733099.gif width=310></a><a href=http://www.sciencedirect.com/science/journal/14733099/13/1 title="Go to table of contents for this volume/issue">Volume 13, Issue 1</a>, January 2013, Pages 77–88</div></p></div></div><ul class="authorGroup noCollab"><li><p><span class=authorDegrees>Dr </span><a class=authorName href=http://www.sciencedirect.com/science/article/pii/S147330991270275X# id=authname_N5d0e3940N5d020df8>Anna P Ralph</a>, <span class=authorDegrees>PhD</span><a class="intra_ref auth_aff" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#aff1 id=baff1 title="Affiliation: a"><sup>a</sup></a><sup>, </sup><a class="intra_ref auth_aff" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#aff2 id=baff2 title="Affiliation: b"><sup>b</sup></a><sup>, </sup><a class="intra_ref auth_aff" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#aff3 id=baff3 title="Affiliation: c"><sup>c</sup></a><sup>, </sup><a class="intra_ref auth_corr" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#cor1 id=bcor1 title="Corresponding author contact information"><img alt="Corresponding author contact information" class=imgLazyJSB src=http://cdn.els-cdn.com/sd/entities/REcor.gif></a><sup>, </sup><a href=mailto:anna.ralph@menzies.edu.au>anna.ralph@menzies.edu.au</a></li></p><li><p><a class=authorName href=http://www.sciencedirect.com/science/article/pii/S147330991270275X# id=authname_N5d0e3940N5d020ee8>Robyn M Lucas</a>, <span class=authorDegrees>PhD</span><a class="intra_ref auth_aff" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#aff4 id=baff4 title="Affiliation: d"><sup>d</sup></a>,</li></p><li><p><a class=authorName href=http://www.sciencedirect.com/science/article/pii/S147330991270275X# id=authname_N5d0e3940N5d020fa8>Mary Norval</a>, <span class=authorDegrees>DSc</span><a class="intra_ref auth_aff" href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#aff5 id=baff5 title="Affiliation: e"><sup>e</sup></a></li></p></ul><ul class=affiliation><li id=aff1><p><sup>a</sup><span>Global and Tropical Health, Menzies School of Health Research, Darwin, NT, Australia</span></li></p><li id=aff2><p><sup>b</sup><span>Sydney Institute for Emerging Infections and Biosecurity, University of Sydney, NSW, Australia</span></li></p><li id=aff3><p><sup>c</sup><span>Department of Medicine, Blacktown Hospital, Blacktown, NSW, Australia</span></li></p><li id=aff4><p><sup>d</sup><span>National Centre for Epidemiology and Population Health, The Australian National University, Canberra, ACT, Australia</span></li></p><li id=aff5><p><sup>e</sup><span>Biomedical Sciences, University of Edinburgh Medical School, Edinburgh, UK</span></li></p></ul><ul class=articleDoi><li><p><a href=http://dx.doi.org/10.1016/S1473-3099%2812%2970275-X id=ddDoi><a href=http://dx.doi.org/10.1016/S1473-3099(12)70275-X>http://dx.doi.org/10.1016/S1473-3099(12)70275-X</a></a>, <a href=http://www.sciencedirect.com/science/help/doi.htm>How to Cite or Link Using DOI</a></li></p></ul><ul class=articleInfo><li class=permissions id=permissions><div class=boxLink><p><a class=olSpawnWindow href="http://www.sciencedirect.com/science?_ob=RedirectURL&_method=outwardLink&_partnerName=936&_eid=1-s2.0-S147330991270275X&_pii=S147330991270275X&_origin=article&_zone=art_page&_targetURL=https%3A%2F%2Fs100.copyright.com%2FAppDispatchServlet%3FpublisherName%3DELS%26contentID%3DS147330991270275X%26orderBeanReset%3Dtrue&_acct=C000029718&_version=1&_userid=582538&amp;md5=a242e325869604fe198c1edc528135dc" rel=nofollow>Permissions & Reprints</a></div></p></li></ul><div class="boxLink permissions"><p><span style=font-size:18px><strong><span style=color:red>(Most of the hyperlinks in this page will not work)</span></strong></span><br><span style=font-size:16px><span style=color:navy><strong>PDF (with references) is attached at the bottom of this page</strong></span></span><br></p></div><div id=refersToAndreferredToBy><dl class=documentThread id=referredToBy><dt><p>Referred to by</dt></p><dd><ul class=reference><li class=title><p><a class=cLink href=http://www.sciencedirect.com/science/article/pii/S1473309913700513><span style=font-weight:700>Corrections</span></a></li></p><li class=source><p><i>The Lancet Infectious Diseases</i>, <i>Volume 13, Issue 3</i>, <i>March 2013</i>, <i>Page 192</i></li></p><li class=external><div style=font-size:11px><p><a class=pdfLink href="http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272254&_user=582538&_pii=S1473309913700513&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2013-03-31&_docsubtype=err&amp;wchp=dGLzVlt-zSkzk&amp;md5=6bf64a33732ec855fcf2dfdba689112a&amp;pid=1-s2.0-S1473309913700513-main.pdf"><img alt border=0 class=pdfImageLink name=pdf src=http://cdn.els-cdn.com/sd/icon_pdf.gif style=vertical-align:middle> PDF (38 K)</a>         </div></p></li></ul></dd><dd><ul class=reference><li class=title><p><a class=cLink href=http://www.sciencedirect.com/science/article/pii/S1473309913700173><span style=font-weight:700>Corrections</span></a></li></p><li class=source><p><i>The Lancet Infectious Diseases</i>, <i>Volume 13, Issue 2</i>, <i>February 2013</i>, <i>Page 106</i></li></p><li class=external><div style=font-size:11px><p><a class=pdfLink href="http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272254&_user=582538&_pii=S1473309913700173&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2013-02-28&_docsubtype=err&amp;wchp=dGLzVlt-zSkzk&amp;md5=ad4de41eafba7cfaeb35058e0dcfb0c5&amp;pid=1-s2.0-S1473309913700173-main.pdf"><img alt border=0 class=pdfImageLink src=http://cdn.els-cdn.com/sd/icon_pdf.gif style=vertical-align:middle> PDF (37 K)</a>         </div></p></li></ul></dd></dl></div><hr id=author1><div class="abstract svAbstract"><h2 class=secHeading id=section_abstract><p>Summary</h2></p><p id=spara80><p>Improved understanding of the association between tuberculosis and vitamin D is needed to inform clinical practice. Vitamin D has both immunostimulatory and immunosuppressive effects relevant to human antimycobacterial responses. Ultraviolet radiation, the main source of vitamin D, also induces immunomodulation and could affect the relation between vitamin D and tuberculosis. Clinical trials of vitamin D supplementation in patients with tuberculosis have produced largely negative results, prompting the review of dosing regimens—an explanation for low 25-hydroxyvitamin D status in patients with active tuberculosis is also needed. The reporting of vitamin D deficiency needs to address assay inaccuracies, rising thresholds to define sufficiency, and scarce knowledge of the concentrations needed for optimum immune responses. Future research to measure the effect of the inflammatory setting on serum concentrations of 25-hydroxyvitamin D, at tuberculosis diagnosis and during recovery, could help to account for 25-hydroxyvitamin D changes in these concentrations in patients with tuberculosis. Studies into the role of vitamin D supplementation in latent tuberculosis justify clinical trials in this population, but pose methodological challenges. Vitamin D trials in patients with active tuberculosis should be done in well selected populations using adequate vitamin D doses, although such doses remain undefined.</p></p></div><hr><h2 class=svArticle id=cesec10><p>Introduction</h2></p><p class="svArticle section" id=para340><p>Tuberculosis is the second most common cause of death from infection worldwide.<span id=bbib1><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib1 id=ancbbib1><sup>1</sup></a></span> Vitamin D deficiency is prevalent across broad geographical boundaries;<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib2 id=bbib2>2</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib3 id=bbib3>3</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib4 id=bbib4>4</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib5 id=bbib5>5</a></sup> an association between the two could be of major relevance to world health.</p></p><p class="svArticle section" id=para350><p><em>Mycobacterium tuberculosis</em> is a human pathogen with efficient transmission and immune evasion strategies. <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib6 id=bbib6>6</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib7 id=bbib7>7</a></sup> After the HIV pandemic, tuberculosis re-emerged as a global emergency,<span id=bbib8><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib8 id=ancbbib8><sup>8</sup></a></span> peaking in 2006 to more than 9 million cases annually, then falling to an estimated 8·8 million by 2010.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib1><sup>1</sup></a></span> The Stop TB Partnership has an ambitious goal to eliminate tuberculosis by 2050 (to less than one case per 1 million every year).<span id=bbib9><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib9 id=ancbbib9><sup>9</sup></a></span> Traditionally classified as either latent or active disease, the outcome of infection with <em>M tuberculosis</em> is now perceived as a continuum. <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib10 id=bbib10>10</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib11 id=bbib11>11</a></sup> For clarity, in this Review we refer to latent tuberculosis infection and active tuberculosis. Prevention, diagnosis, and management of both active tuberculosis and latent infection remain challenging, despite substantial improvements in diagnostic tests, <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib12 id=bbib12>12</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib13 id=bbib13>13</a></sup> new drugs for active tuberculosis, <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib14 id=bbib14>14</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib15 id=bbib15>15</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib16 id=bbib16>16</a></sup> and new regimens for latent infection.<span id=bbib17><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib17 id=ancbbib17><sup>17</sup></a></span></p></p><p class="svArticle section" id=para360><p>Drawbacks with tuberculosis treatment regimens, particularly rising drug resistance and HIV–tuberculosis co-infection, are driving the need for novel treatment approaches. Strategies to accelerate recovery and reduce treatment durations include the development of new antimicrobial agents and the investigation of adjunctive immunotherapies; both are priority areas of tuberculosis research.<span id=bbib18><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib18 id=ancbbib18><sup>18</sup></a></span> Mechanisms of action of potential adjunctive treatments include promotion of T-helper-1 (Th1) antimycobacterial immune responses (eg, administration of interferon gamma),<span id=bbib19><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib19 id=ancbbib19><sup>19</sup></a></span> upregulation of host innate (ie, macrophage) antimycobacterial immune responses (eg, vitamin D and nitric oxide),<span id=bbib20><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib20 id=ancbbib20><sup>20</sup></a></span> decrease of immunopathology mediated tissue damage because of excessive inflammatory responses (eg, corticosteroids),<span id=bbib21><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib21 id=ancbbib21><sup>21</sup></a></span> and alteration of the metabolic state of tuberculosis bacilli to shift them out of a non-replicative, antibiotic-resistant state (eg, tumour necrosis factor α <a class=wiki href=TNF%CE%B1 rel>TNFα</a> inhibitors).<span id=bbib22><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib22 id=ancbbib22><sup>22</sup></a></span> There has been much hope that vitamin D might fulfil at least some of these actions as a potential adjunctive treatment in active or latent tuberculosis.</p></p><p class="svArticle section" id=para370><p>Vitamin D is derived from endogenous synthesis after exposure of the skin to solar ultraviolet radiation. Receptors for its active form, 1,25-dihydroxyvitamin D, are widely expressed in human cells, including monocytes and macrophages, dendritic, T cells, B cells, and natural killer cells.<span id=bbib23><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib23 id=ancbbib23><sup>23</sup></a></span> The effects of 1,25-dihydroxyvitamin D are immunostimulatory in monocytes and macrophages and immunosuppressive in dendritic and T cells. Ultraviolet radiation causes immune changes too, mainly downregulatory, in antigens encountered close to the time of the exposure.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib24 id=bbib24>24</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib25 id=bbib25>25</a></sup></p></p><p class="svArticle section" id=para380><p>Basic science,<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib26 id=bbib26>26</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27 id=bbib27>27</a></sup> clinical research,<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib28 id=bbib28>28</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib29 id=bbib29>29</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib30 id=bbib30>30</a></sup> population studies,<span id=bbib31><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib31 id=ancbbib31><sup>31</sup></a></span> and historical treatment practices (eg, phototherapy and cod-liver oil)<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib32 id=bbib32>32</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib33 id=bbib33>33</a></sup> suggest that inexpensive, accessible vitamin D could play an important part in the treatment of tuberculosis. Sufficiency in vitamin D has been hypothesised to decrease the risk of infection with tuberculosis after exposure,<span id=bbib34><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib34 id=ancbbib34><sup>34</sup></a></span> limits the progression from latent to active tuberculosis,<span id=bbib35><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib35 id=ancbbib35><sup>35</sup></a></span> and, as an adjunct to antimicrobial treatment, decreases the duration and improves the effectiveness of treatment.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib20>20</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib28>28</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib30>30</a></sup></p></p><p class="svArticle section" id=para390><p>Questions about the relation between tuberculosis, vitamin D, and ultraviolet radiation are largely unexplored. These include reconciliation of contradictory immunological actions of 1,25-dihydroxyvitamin D related to the balance between innate immunity (antimicrobial peptides and macrophages in particular) and adaptive immunity, understanding of the immunological effects of exposure to ultraviolet radiation (a potentially important confounder of the vitamin D–tuberculosis relation), and consideration of alternative hypotheses that explain the common finding of low vitamin D status in patients with active tuberculosis. We reviewed the scientific literature to provide evidence, explore contradictions, and suggest alternative hypotheses.</p></p><div class=page_fragment id=frag_2><h2 class=svArticle id=cesec20><p>Vitamin D</h2></p><h3 class=svArticle id=cesec30><p>Background</h3></p><p class="svArticle section" id=para400><p>When 7-dehydrocholesterol in the plasma membrane of human keratinocytes is exposed to ultraviolet B (UVB) radiation, it is converted to previtamin D<sub>3</sub>, followed by a thermal reaction to form vitamin D<sub>3</sub> (cholecalciferol). Some foods contain vitamin D<sub>3</sub> or vitamin D<sub>2</sub>, which is synthesised by plants after UVB irradiation; however, these only contribute small amounts of the total vitamin D requirements in most individuals. The physiological effects of D<sub>2</sub> and D<sub>3</sub> are interchangeable, although oral vitamin D<sub>3</sub> is more effective in raising serum 25-hydroxyvitamin D concentration than is D<sub>2</sub>.<span id=bbib36><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib36 id=ancbbib36><sup>36</sup></a></span> Vitamin D is fat soluble, and, as with the vitamin D metabolites, is carried in the circulation by hepatically produced vitamin D-binding protein. In the liver, vitamin D undergoes hydroxylation by a 25-hydroxylase to form 25-hydroxyvitamin D, which is converted to the biologically active steroid hormone 1,25-dihydroxyvitamin D by 1α-hydroxylase enzyme. The actions of the hormone are mediated either through ligation with a nuclear vitamin D receptor (VDR) to regulate gene transcription, resulting in genomic responses, or via membrane rapid-response receptors.<span id=bbib37><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib37 id=ancbbib37><sup>37</sup></a></span> These receptors are distributed in most human tissues. Thus, 1,25-dihydroxyvitamin D can be generated by tissues expressing 1α-hydroxylase and act via local VDRs. The 1α-hydroxylase gene, <em>CPY27B1,</em> is primarily expressed in the kidney under normal conditions. Expression in a wide range of other human cells, including activated macrophages, is important in disease states.<span id=bbib38><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib38 id=ancbbib38><sup>38</sup></a></span> Production of 1,25-dihydroxyvitamin D in renal cells is under negative feedback control through induction by the hormone of 24-hydroxylase, which catabolises 25-hydroxyvitamin D as well as 1,25-dihydroxyvitamin D. This feedback does not happen in macrophages, perhaps because macrophages express a splice variant of the 24-hydroxylase gene.<span id=bbib39><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib39 id=ancbbib39><sup>39</sup></a></span> Thus, hypercalcaemia is possible in granulomatous diseases that are characterised by macrophage activation, such as sarcoidosis and tuberculosis.</p></p><p class="svArticle section" id=para410><p>Determinants of vitamin D status include exposure to UVB radiation emitted by the sun (which varies by latitude, albedo, altitude, season, time of day, pollution, and cloud cover),<span id=bbib40><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib40 id=ancbbib40><sup>40</sup></a></span> clothing, dietary intake, body-mass index, serum cholesterol,<span id=bbib41><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib41 id=ancbbib41><sup>41</sup></a></span> and genetic factors such as skin pigmentation and polymorphisms in or near genes encoding the VDR and enzymes of the vitamin D metabolic pathway (eg, 7-dehydrocholesterol reductase, 25-hydroxylase, 24-hydroxylase, and possibly 1α-hydroxylase).<span id=bbib42><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib42 id=ancbbib42><sup>42</sup></a></span></p></p><h3 class=svArticle id=cesec40><p>Measurement, reference ranges, and supplementation</h3></p><p class="svArticle section" id=para420><p>Vitamin D status is inferred from the concentration of total 25-hydroxyvitamin D in serum. The methods used to detect this concentration, however, (eg, chemiluminescence and radioimmunoassays)<span id=bbib43><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib43 id=ancbbib43><sup>43</sup></a></span> lack accuracy, reproducibility, and sensitivity.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib44 id=bbib44>44</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib45 id=bbib45>45</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib46 id=bbib46>46</a></sup> Other assay methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) can distinguish 25-hydroxyvitamin D<sub>2</sub> and 25-hydroxyvitamin D<sub>3</sub> concentrations and are user dependent.<span id=bbib47><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib47 id=ancbbib47><sup>47</sup></a></span> A vitamin D standardisation programme is underway, using LC-MS/MS to standardise measurements of serum 25-hydroxyvitamin D globally.<span id=bbib48><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib48 id=ancbbib48><sup>48</sup></a></span></p></p><p class="svArticle section" id=para430><p>In addition to drawbacks with measurement, there is no consensus on the reference values that define vitamin D sufficiency and deficiency (<span id=btbl1><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl1 id=ancbtbl1>table 1</a></span>).<span id=bbib54><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54 id=ancbbib54><sup>54</sup></a></span> Rising reference ranges have caused an increase in the prevalence of vitamin D deficiency, including in low-latitude settings.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib2>2</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib3>3</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib4>4</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib5>5</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib58 id=bbib58>58</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib59 id=bbib59>59</a></sup> In the 1990s, a common threshold for deficiency was less than 25 nmol/L, now, concentrations of up to 125 nmol/L are advocated.<span id=bbib56><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib56 id=ancbbib56><sup>56</sup></a></span> The 2010 US Institute of Medicine statement defined vitamin D sufficiency as a serum concentration of 50 nmol/L 25-hydroxyvitamin D or higher for adults and children.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54><sup>54</sup></a></span> In addition to the shifting targets, some evidence exists for an increase in vitamin D deficiency in populations.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54><sup>54</sup></a></span> Although samples were not run in parallel and assay drift is a recognised problem,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54><sup>54</sup></a></span> the mean serum 25-hydroxyvitamin D concentration in participants in the large US National Health and Nutrition Examination Surveys fell from 75 nmol/L in 1988–1994 to 60 nmol/L in 2001–2004, attributed in part to increased sun protection in response to skin cancer campaigns.<span id=bbib60><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib60 id=ancbbib60><sup>60</sup></a></span></p></p><div class="figTblUpiOuter svArticle" id=table_tbl1><div class=textboxdefault><dl class=table id=tbl1><dd class=lblCap><p class=caption><p><span class=label>Table 1. </span>Reference ranges for vitamin D status</p></p></dd><dd class=table><table><col><col><col><col><col><col><thead><tr><th colspan=1 rowspan=1></th><th colspan=1 rowspan=1><p><strong class=boldFont>Deficiency</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Insufficiency</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Adequacy</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Optimal</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Comment</strong></th></p></tr></thead><tbody><tr><td colspan=6 rowspan=1><p><strong class=boldFont>Adults</strong></td></p></tr><tr><td colspan=1 rowspan=1><p>Harrison&rsquo;s Principles of Internal Medicine, 1998<span id=bbib49><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib49 id=ancbbib49><sup>49</sup></a></span></td></p><td colspan=1 rowspan=1></td><td colspan=1 rowspan=1></td><td colspan=1 rowspan=1><p>“Adequacy” varies according to assay and laboratory, from 20 to 200 nmol/L</td></p><td colspan=1 rowspan=1></td><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>Australian and New Zealand guidelines, 2005<span id=bbib50><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib50 id=ancbbib50><sup>50</sup></a></span></td></p><td colspan=1 rowspan=1><p>&lt;12·5 nmol/L</td></p><td colspan=1 rowspan=1><p>12·5–50·0 nmol/L</td></p><td colspan=1 rowspan=1><p>>50 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>Extra categories of moderate and mild deficiency are summarised as insufficiency</td></p></tr><tr><td colspan=1 rowspan=1><p>Dawson-Hughes et al, 2005<span id=bbib51><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib51 id=ancbbib51><sup>51</sup></a></span></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>≥50 nmol/L, ≥70 nmol/L, ≥75 nmol/L, or ≥80 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>Consensus not reached by a panel of five experts</td></p></tr><tr><td colspan=1 rowspan=1><p>Hollis, 2005<span id=bbib52><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib52 id=ancbbib52><sup>52</sup></a></span></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>>80 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>Holick, 2007<span id=bbib53><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib53 id=ancbbib53><sup>53</sup></a></span></td></p><td colspan=1 rowspan=1><p>&lt;50 nmol/L</td></p><td colspan=1 rowspan=1><p>50–75 nmol/L</td></p><td colspan=1 rowspan=1><p>>75 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>US Institute of Medicine, 2010<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54><sup>54</sup></a></span></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>≥50 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>Pearce and Cheetham, 2010<span id=bbib55><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib55 id=ancbbib55><sup>55</sup></a></span></td></p><td colspan=1 rowspan=1><p>&lt;20 nmol/L</td></p><td colspan=1 rowspan=1><p>25–50 nmol/L</td></p><td colspan=1 rowspan=1><p>50–75 nmol/L</td></p><td colspan=1 rowspan=1><p>>75 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>Vitamin D Council, 2011<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib56><sup>56</sup></a></span></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>>125 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p><strong class=boldFont>Children</strong></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1></td><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p></tr><tr><td colspan=1 rowspan=1><p>Wagner and Greer, 2008<span id=bbib57><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib57 id=ancbbib57><sup>57</sup></a></span></td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>≥50 nmol/L</td></p><td colspan=1 rowspan=1><p>..</td></p><td colspan=1 rowspan=1><p>Consensus not reached on concentration to define vitamin D insufficiency for infants and children</td></p></tr></tbody></table></dd><dd><p class=legend><p>Data are serum 25-hydroxyvitamin.</p></p></dd></dl></div></div><p class="svArticle section" id=para440><p>Evidence from several studies, often with small sample sizes or very specific populations or both (eg, elderly, epileptic, with psoriasis), which used small dose ranges of artificial ultraviolet radiation,<span id=bbib61><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib61 id=ancbbib61><sup>61</sup></a></span> suggest that whole-body exposure to ultraviolet radiation, sufficient to cause just-detectable erythema of the skin, is comparable, in raising 25-hydroxyvitamin D concentrations, to ingestion of 10 000 IU of oral vitamin D.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib62 id=bbib62>62</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib63 id=bbib63>63</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib64 id=bbib64>64</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib65 id=bbib65>65</a></sup> However, translation of these findings into natural sun exposure situations in which variable body surface areas are exposed, individuals are upright rather than horizontal (thus receiving around a third of the dose of ultraviolet radiation, depending on solar elevation), and the level of ambient UVB varies with latitude, season, time of day, cloud cover, and urban or rural environments is difficult.<span id=bbib66><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib66 id=ancbbib66><sup>66</sup></a></span> Several UK studies show that recommended casual (short) sun exposure, even during summer, is generally insufficient to raise 25-hydroxyvitamin D to optimum concentrations,<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib67 id=bbib67>67</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib68 id=bbib68>68</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib69 id=bbib69>69</a></sup> particularly in deeply pigmented populations.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib69 id=ancbbib69><sup>69</sup></a></span> Strategies to optimise vitamin D status by oral intake in adults differ widely, depending on whether physiological replacement or pharmacological dosing is desired, and whether daily or intermittent bolus treatment is preferred. The minimum vitamin D<sub>3</sub> requirement is 400 IU/day across all ages,<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54>54</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib55>55</a></sup> but treatment doses of 10 000 IU daily, or up to 600 000 IU given as a one-off bolus in adults, have been advocated to treat deficiency in 2010 guidelines.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib57><sup>57</sup></a></span> Because rickets, resulting from vitamin D deficiency in infants, continues to occur in high-resource settings,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib57><sup>57</sup></a></span> supplementation (400 IU/day) is recommended as a routine for infants (aged 0–12 months).</p></p><p class="svArticle section" id=para450><p>Whether the 25-hydroxyvitamin D concentrations regarded as sufficient for bone health are applicable to other vitamin D functions such as immunity, remains unknown. Part of the drive to increase recommended reference ranges of vitamin D, rather than the use of population distributions, derives from studies of bone biomarkers such as parathyroid hormone.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib52><sup>52</sup></a></span> However, no such markers are available to estimate the optimum 25-hydroxyvitamin D concentration needed for the non-skeletal functions of vitamin D. The biological significance of the natural seasonal variation in serum 25-hydroxyvitamin D, which is common in people living outside tropical latitudes is poorly understood. Vieth<span id=bbib70><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib70 id=ancbbib70><sup>70</sup></a></span> hypothesises that such variation might be harmful, and that delays in cellular responses to changing concentrations could account for the increased risk of prostate and pancreatic cancers in people with high serum 25-hydroxyvitamin D living in settings with low ultraviolet exposure. Sudden changes in 25-hydroxyvitamin D from large doses of vitamin D could also be associated with adverse outcomes: a study in which 500 000 IU vitamin D<sub>3</sub> boluses were given annually showed an association with increased risk of fall and fracture.<span id=bbib71><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib71 id=ancbbib71><sup>71</sup></a></span> These uncertainties, and the limitations of 25-hydroxyvitamin D assays and changing reference ranges, should be considered when associations between tuberculosis and vitamin D are examined.</p></p></div><div class=page_fragment id=frag_3><h3 class=svArticle id=cesec50><p>Vitamin D gene polymorphisms</h3></p><p class="svArticle section" id=para460><p>A contribution of vitamin D insufficiency to worse outcomes after infection with tuberculosis could be supported by finding an association with genetic polymorphisms within vitamin D-related genes. Most studies have focused on <em>VDR</em> gene variants that could affect activity of the receptor and therefore its downstream functions. For example, the <em>Fok</em>I F allele is more transcriptionally active than the f allele, <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib72 id=bbib72>72</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib73 id=bbib73>73</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib74 id=bbib74>74</a></sup> with increased responsiveness to 1,25-dihydroxyvitamin D.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib73 id=ancbbib73><sup>73</sup></a></span> A meta-analysis of 23 studies showed changes in risk of tuberculosis development associated with VDR polymorphisms in Asian populations: increased risk with the ff genotype of the <em>Fok</em>I polymorphism, and decreased risk with the bb genotype of the <em>Bsm</em>I polymorphism.<span id=bbib75><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib75 id=ancbbib75><sup>75</sup></a></span> Importantly, the effect of genotype within the context of vitamin D status has not been examined rigorously—ie, the effect of a less efficient VDR might be more apparent at low, compared with high, 25-hydroxyvitamin D concentrations. Wilkinson and colleagues<span id=bbib76><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib76 id=ancbbib76><sup>76</sup></a></span> showed that TT or Tt alleles of <em>Taq</em>I were associated with increased tuberculosis risk only in people with vitamin D deficiency, and the ff allele of <em>Fok</em>I was associated with increased risk only in those with non-detectable 25-hydroxyvitamin D. The response to treatment in relation to <em>VDR</em> genotype has been noted in several studies: rapid treatment responses occurred in patients with TT<span id=bbib77><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib77 id=ancbbib77><sup>77</sup></a></span> or tt alleles<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib29 id=ancbbib29><sup>29</sup></a></span> of <em>Taq</em>I, FF<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib77><sup>77</sup></a></span> or ff<span id=bbib78><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib78 id=ancbbib78><sup>78</sup></a></span> alleles of <em>Fok</em>I, and the AA allele of <em>Apa</em>I.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib78><sup>78</sup></a></span> No variation in treatment responses by <em>VDR</em> genotype in relation to serum 25-hydroxyvitamin D concentration has been investigated to date.</p></p><p class="svArticle section" id=para470><p>Few studies have examined polymorphisms in <em>CYP27B1</em> (encoding 1α-hydroxylase) and <em>GC</em> (encoding vitamin D binding protein) with respect to tuberculosis and vitamin D. For <em>CYP27B1</em>, polymorphisms are unrelated to susceptibility to active tuberculosis.<span id=bbib79><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib79 id=ancbbib79><sup>79</sup></a></span> Generally, <em>GC</em> genotypes are not associated with active tuberculosis,<span id=bbib80><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib80 id=ancbbib80><sup>80</sup></a></span> but in Gujarati Asians, the <em>GC</em>2/2 genotype is strongly linked with susceptibility to active tuberculosis compared with the <em>GC</em>1/1 genotype, although only in those with low (&lt;20 nmol/L) 25-hydroxyvitamin D levels.<span id=bbib81><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib81 id=ancbbib81><sup>81</sup></a></span></p></p><h3 class=svArticle id=cesec60><p>Immunomodulatory effects of vitamin D</h3></p><p class="svArticle section" id=para480><p>Most effects of 1,25-dihydroxyvitamin D are immunosuppressive, but some, important in controlling <em>M tuberculosis</em> infection, are immunostimulatory (<span id=bbox1><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#box1 id=ancbbox1>panel 1</a></span>). <sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib26>26</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27>27</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib86 id=bbib86>86</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib89 id=bbib89>89</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib91 id=bbib91>91</a></sup> In brief, activation of macrophages via toll-like receptor<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib26 id=ancbbib26><sup>26</sup></a></span> and interferon gamma,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27 id=ancbbib27><sup>27</sup></a></span> reversal of phagosome maturation arrest,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib86 id=ancbbib86><sup>86</sup></a></span> and autophagy<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27><sup>27</sup></a></span> are all crucial components of the immune response to <em>M tuberculosis</em>; each has been shown to use 1,25-dihydroxyvitamin D. Contrastingly, the suppression of acquired immune responses by 1,25-dihydroxyvitamin D could impair clearance of <em>M tuberculosis</em>, particularly through the downregulation of Th1 and Th17-mediated responses and generation of regulatory T cells.<span id=bbib82><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib82 id=ancbbib82><sup>82</sup></a></span> In peripheral blood mononuclear cells infected in vitro with <em>M tuberculosis</em>, 1,25-dihydroxyvitamin D changes the balance in cytokine production towards an anti-inflammatory profile (downregulation of interleukin 6, TNFα, and interferon gamma)<span id=bbib92><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib92 id=ancbbib92><sup>92</sup></a></span> through reduced expression of several pattern recognition receptors, such as TLR-2 and Dectin-1. How this can be reconciled with the increased risk of tuberculosis infection after inhibition of interferon gamma, interleukin 12, and TNFα is not clear.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib38><sup>38</sup></a></span> The mild T-cell suppression caused by 1,25-dihydroxyvitamin D, combined with its innate immunostimulatory effects, could be beneficial by mitigating cell-mediated immunopathology in active tuberculosis (akin to the use of corticosteroids in tuberculosis meningitis), while promoting <em>M tuberculosis</em> killing through activated macrophage pathways.</p></p><div class=textboxdefault id=box1><div id=tde><div class=textboxCaption><p><span class=textboxHead>Panel 1. </span><span class=caption>Major immunomodulatory effects of 1,25-dihydroxyvitamin D</span></div></p><div class=textboxBody><p class="svArticle section" id=para10><p><strong class=boldFont>Adaptive responses (predominantly immunosuppressive)</strong><sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib82>82</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib83 id=bbib83>83</a></sup></p></p><dl class=listitem id=list_celist10><dt class=label><p>•Inhibits T-helper (Th) 1 cytokines (eg, interleukin 2, interferon gamma)</dt></p><dt class=label><p>•Promotes Th2 cytokines (eg, interleukin 4, 5, and 10)</dt></p><dt class=label><p>•Suppresses antigen presentation with reduced interleukin 12 production</dt></p><dt class=label><p>•Inhibits Th17 proliferation and interleukin 17 production</dt></p><dt class=label><p>•Promotes number and function of regulatory T cells</dt></p><dt class=label><p>•Inhibits differentiation and proliferation of B cells and production of immunoglobulin</dt></p></dl><p class="svArticle section" id=para90><p><strong class=boldFont>Innate responses (predominantly immunostimulatory)</strong></p></p><dl class=listitem id=list_celist20><dt class=label><p>•Inhibits toll-like receptor-mediated production of interleukin 12 and interleukin 23<span id=bbib84><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib84 id=ancbbib84><sup>84</sup></a></span></dt></p><dt class=label><p>•Upregulates expression of the cathelicidin gene <em>CAP18</em> (ie, <em>CAMP</em>) in macrophages, leading to the production of the antimicrobial peptide, LL-37, which mediates <em>Mycobacterium tuberculosis</em> cell death<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib26><sup>26</sup></a></span></dt></p><dt class=label><p>•Promotes autophagy via cathelicidin, which enters the autophagosome vacuole containing <em>M tuberculosis</em> to mediate cell death<span id=bbib85><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib85 id=ancbbib85><sup>85</sup></a></span></dt></p><dt class=label><p>•Reverses <em>M tuberculosis</em>-induced phagosome maturation arrest via a phosphoinositide 3-kinase pathway<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib86><sup>86</sup></a></span> and via autophagy</dt></p></dl><p class="svArticle section" id=para150><p><strong class=boldFont>Adaptive and innate responses</strong></p></p><dl class=listitem id=list_celist30><dt class=label><p>•Inhibits differentiation and maturation of dendritic cells<span id=bbib87><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib87 id=ancbbib87><sup>87</sup></a></span></dt></p><dt class=label><p>•Increases number of invariant natural killer T cells and their cytokine production<span id=bbib88><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib88 id=ancbbib88><sup>88</sup></a></span></dt></p><dt class=label><p>•Induces synthesis of antimicrobial peptides including LL-37, after macrophage activation is achieved in response to interferon gamma released from activated T cells<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27><sup>27</sup></a></span></dt></p></dl><p class="svArticle section" id=para200><p><strong class=boldFont>Other</strong></p></p><dl class=listitem id=list_celist40><dt class=label><p>•Inhibits production of matrix metalloproteinases (MMPs) in human peripheral blood mononuclear cells. MMP production in the lung is induced by <em>M tuberculosis</em> and could contribute to cavity formation; if 1,25-dihydroxyvitamin can also inhibit MMP production in the lung, it could provide protection against tuberculosis-induced lung pathology<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib89 id=ancbbib89><sup>89</sup></a></span></dt></p><dt class=label><p>•Vitamin D-binding protein has independent immune functions—eg, deglycosylated protein stimulates macrophages<span id=bbib90><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib90 id=ancbbib90><sup>90</sup></a></span></dt></p></dl></div></div></div><p class="svArticle section" id=para490><p>The effect of supplemental vitamin D on in-vivo immune responses to <em>M tuberculosis</em> is rarely studied. One report included 192 tuberculosis contacts, randomly assigned to receive one oral dose of vitamin D (2·5 mg, 100 000 IU) or placebo.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib30 id=ancbbib30><sup>30</sup></a></span> A substantial improvement in antimycobacterial immunity was noted in the vitamin D versus placebo group, as shown by the growth restriction of recombinant mycobacteria (BCG-lux assay) in whole blood taken from each patient. This response is regarded as a demonstration of innate immunity and, contrastingly, the acquired response (as measured by interferon gamma secretion after stimulation of blood cells with mycobacterial antigens in vitro) did not differ between the groups. Another study involved south Asian immigrants to the UK with low serum 25-hydroxyvitamin D concentrations who were UVB irradiated, resulting in an increase in these concentrations to about 50 nmol/L. However, no change in their antimycobacterial immunity, assessed by restriction of growth of BCG-lux, occurred.<span id=bbib93><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib93 id=ancbbib93><sup>93</sup></a></span></p></p><h2 class=svArticle id=cesec70><p>Ultraviolet radiation-induced immunological effects and tuberculosis</h2></p><p class="svArticle section" id=para500><p>Ultraviolet radiation is the major source of vitamin D and its immunological effects should therefore be assessed alongside those of vitamin D.<span id=bbib94><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib94 id=ancbbib94><sup>94</sup></a></span> Exposure of animals and human beings to ultraviolet light results in downregulation of T and B-cell response to various antigens, including tumour antigens, contact sensitisers, microorganisms, and alloantigens.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib25 id=ancbbib25><sup>25</sup></a></span> Immunomodulation pathways vary depending on the antigen; the spectrum, dose and frequency of radiation exposure, time between exposure and application of the antigen, and the involvement of primary or memory immune responses. Differences exist between local immunosuppression, in which the antigen is applied directly to the irradiated body site, and systemic immunosuppression, in which the antigen is applied to a site distant from the irradiated area. The main outcome of local immunosuppression is the promotion of antigen-specific regulatory T and B cells in local lymph nodes that suppress immunity.<span id=bbib95><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib95 id=ancbbib95><sup>95</sup></a></span> In systemic immunosuppression, mediators such as prostaglandins might be released from the irradiated site and a systemic increase in regulatory T cells and activation of natural killer T cells that promote tolerance could occur.<span id=bbib96><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib96 id=ancbbib96><sup>96</sup></a></span></p></p><p class="svArticle section" id=para510><p>Irradiation of human skin with ultraviolet light produces antimicrobial peptides, possibly through vitamin D, including β-defensin 2 and β-defensin 3.<span id=bbib97><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib97 id=ancbbib97><sup>97</sup></a></span> Thus, although exposure to ultraviolet light suppresses adaptive immunity, it can also foster innate mechanisms that could be important in controlling bacterial infections, especially on epidermal surfaces. In human skin cells in vitro and mouse skin in vivo, the topical application of 1,25-dihydroxyvitamin D after exposure to ultraviolet radiation can reduce DNA damage and apoptosis of skin cells via the rapid non-genomic pathway.<span id=bbib98><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib98 id=ancbbib98><sup>98</sup></a></span> Additionally, 1,25-dihydroxyvitamin D reduces ultraviolet-induced suppression in contact hypersensitivity in mice;<span id=bbib99><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib99 id=ancbbib99><sup>99</sup></a></span> thus, 1,25-dihydroxyvitamin D is protective against several of the immunosuppressive effects of ultraviolet radiation.</p></p><p class="svArticle section" id=para520><p>Different approaches point to an effect of exposure to ultraviolet radiation in tuberculosis transmission. First, tuberculosis has an annual seasonal pattern in many countries. Fares<span id=bbib100><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib100 id=ancbbib100><sup>100</sup></a></span> reviewed 12 studies involving data from 11 countries or regions and recorded a peak of cases (defined as time of notification, frequently about 3 months after onset of symptoms) in spring and summer. Similar findings of a spring peak have been reported from Cape Town<span id=bbib101><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib101 id=ancbbib101><sup>101</sup></a></span> and New York.<span id=bbib102><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib102 id=ancbbib102><sup>102</sup></a></span> This pattern could be attributed to high <em>M tuberculosis</em> transmission risk during winter months and low vitamin D status at this time of the year leading to impaired innate immune responses and perhaps reactivation of latent infection. Additionally, cough during winter could erroneously be attributed to non-tuberculous causes, with tuberculosis diagnoses being delayed until spring.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib102><sup>102</sup></a></span> Alternatively, infection in winter could be controlled, allowing the ultraviolet-induced immunosuppression after high exposure to solar ultraviolet radiation in spring to be sufficient to enable active disease.</p></p></div><div class=page_fragment id=frag_4><p class="svArticle section" id=para530><p>Second, ultraviolet irradiation can reduce the immune response to <em>M tuberculosis</em> in a guineapig model.<span id=bbib103><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib103 id=ancbbib103><sup>103</sup></a></span> Animals vaccinated with BCG, then irradiated with ultraviolet light, showed suppression of the delayed hypersensitivity response to purified protein derivative.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib103><sup>103</sup></a></span> On challenge with an aerosol of live <em>M tuberculosis</em>, the pulmonary microbial load was increased, and in-vitro lymphoproliferative response to purified protein derivative reduced, in irradiated compared with non-irradiated animals. Third, in the only meta-analysis of vaccine efficacy that considered location, Colditz and colleagues<span id=bbib104><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib104 id=ancbbib104><sup>104</sup></a></span> showed that tuberculosis protection conferred by BCG increased with distance from the equator. Others have also noted that protection is reduced in tropical regions.<span id=bbib105><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib105 id=ancbbib105><sup>105</sup></a></span> Ultraviolet-induced immunosuppression, greatest in equatorial areas, could account for this finding although many additional changes occur with latitude such as exposure to other pathogens, diet, clothing, temperature, and daylight hours. The moderating role of skin pigmentation in ultraviolet-induced vitamin D production could also be relevant. Finally, ultraviolet irradiation reduces memory responses to BCG in humans.<span id=bbib106><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib106 id=ancbbib106><sup>106</sup></a></span> Individuals immunised with BCG were exposed to suberythemal solar simulated ultraviolet radiation before challenge with purified protein derivative on the irradiated and a distant non-irradiated site—the Mantoux reaction was suppressed at the irradiated site but not at the distant site.</p></p><p class="svArticle section" id=para540><p>Effects of exposure to ultraviolet radiation and vitamin D are difficult to examine separately in studies of human beings. Such research would necessitate assessment of ultraviolet radiation exposure with personal ultraviolet dosimeters (frequently worn as wristbands),<span id=bbib107><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib107 id=ancbbib107><sup>107</sup></a></span> categorisation of skin type, and measurement of serum 25-hydroxyvitamin D concentration. Both experimental studies on animals and epidemiological studies in human beings suggest independent effects for ultraviolet radiation and vitamin D in the autoimmune disease multiple sclerosis, but we are unaware of any research specifically assessing antimycobacterial responses.</p></p><p class="svArticle section" id=para550><p>Studies reviewed here suggest that ultraviolet radiation could have a predominantly immunosuppressive role in tuberculosis through the downregulation of acquired immunity, while potentially promoting the production of vitamin D.</p></p><h2 class=svArticle id=cesec80><p>Historical perspective</h2></p><p class="svArticle section" id=para560><p>In the 19th century, cod-liver oil was used in Europe to prevent childhood diseases such as rickets and tuberculosis.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib33>33</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib108 id=bbib108>108</a></sup> Although not a cure, a benefit in patients with tuberculosis was weight gain.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib108 id=ancbbib108><sup>108</sup></a></span> It was sometimes given in large doses (0·5–1·0 pint every 4–8 days or one or two tablespoons two to four times daily). The chemical structures of the vitamins D were discovered by Windaus and colleagues<span id=bbib109><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib109 id=ancbbib109><sup>109</sup></a></span> in the 1930s and the antirachitic component of cod-liver oil, identified in rats, was identical to vitamin D<sub>3</sub>. One tablespoon of cod-liver oil contains about 1360 IU vitamin D<sub>3</sub>, the highest level in any food, in addition to vitamin A and omega-3 fatty acids.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib108><sup>108</sup></a></span></p></p><p class="svArticle section" id=para570><p>The use of cod-liver oil in the treatment of tuberculosis fell during the early 20th century because of its unpleasant taste and the increased popularity of heliotherapy (sun exposure) and phototherapy (exposure to an artificial light source). In the 1940s, however, several physicians treated lupus vulgaris (cutaneous tuberculosis) with large doses of vitamin D<sub>2</sub>: 150 000 IU/day orally.<span id=bbib110><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib110 id=ancbbib110><sup>110</sup></a></span> In one report, 56% of patients were cured and 20% were unresponsive after treatment, with hypercalcaemia as a recognised complication.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib110><sup>110</sup></a></span> The toxicity threshold for vitamin D is now estimated at 10 000–50 000 IU/day.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib54><sup>54</sup></a></span> In Jan 2012, hypercalcaemia was also noted in a case report after high-dose vitamin D supplementation in patients with tuberculosis.<span id=bbib111><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib111 id=ancbbib111><sup>111</sup></a></span> Vitamin D was also used in the treatment of disseminated tuberculosis: a 1948 case report described success after oral administration of 100 000 IU cholecalciferol daily.<span id=bbib112><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib112 id=ancbbib112><sup>112</sup></a></span> Nevertheless, vitamin D was replaced by antibiotics from the second half of the 20th century, until its return recently.</p></p><p class="svArticle section" id=para580><p>Heliotherapy was introduced in the mid-1800s with the opening of a thermal treatment station in Slovenia.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib32 id=ancbbib32><sup>32</sup></a></span> A great advance was made by Finsen<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib32><sup>32</sup></a></span> who used filtered sunlight in 1893 to treat cutaneous tuberculosis, and in 1901, created a carbon arc lamp that emitted concentrated ultraviolet radiation–the first source of phototherapy. Antimicrobial peptides induced in keratinocytes by exposure to ultraviolet light, via a vitamin D-related mechanism, have been postulated to provide an explanation for this result. However, the spectrum of the lamp was recorded recently and contained no UVB, hence vitamin D production in patients irradiated using this technique is unlikely; an alternative suggestion is that the longer UVA rays might kill <em>M tuberculosis</em> by a photodynamic mechanism because the bacteria contains coproporphyrin III.<span id=bbib113><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib113 id=ancbbib113><sup>113</sup></a></span> Additionally, germicidal ultraviolet lamps, which emit short-wavelength UVC radiation and exert a direct bactericidal effect, have a proven effectiveness against airborne <em>M tuberculosis</em>.<span id=bbib114><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib114 id=ancbbib114><sup>114</sup></a></span></p></p><p class="svArticle section" id=para590><p>Interest in natural exposure to sunlight as a tuberculosis treatment continued to develop. A 1903 study<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib32><sup>32</sup></a></span> of graded sun exposures showed that time-to-cure was shorter than when carbon arc lamps were used. From the 1920s until the antibiotic era, heliotherapy became the most popular method of tuberculosis treatment in Europe and the USA, although it was contraindicated for pulmonary tuberculosis in some studies.<span id=bbib115><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib115 id=ancbbib115><sup>115</sup></a></span> Notably, long-term rest and a nourishing diet were deemed to be as essential as sun exposure.</p></p><p class="svArticle section" id=para600><p>Exposure to the sun and dietary vitamin D were thus thought to help in the treatment of specific forms of tuberculosis, although other components of these strategies might have contributed to any true therapeutic effects. There were also substantial changes in social environments in high-income countries, which reduced the risks of <em>M tuberculosis</em> transmission.</p></p><h3 class=svArticle id=cesec90><p>Observational studies of serum 25-hydroxyvitamin D concentration</h3></p><p class="svArticle section" id=para610><p>In-vivo studies in human beings have been unable to clearly address whether vitamin D status affects susceptibility to tuberculosis infection, development of active disease from latency, or treatment response. This is because most studies of serum 25-hydroxyvitamin D concentration in patients with active tuberculosis are cross-sectional, and are therefore unable to show whether low 25-hydroxyvitamin D levels are a result of, rather than a risk factor for, the disease process (<span id=btbl2><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2 id=ancbtbl2>table 2</a></span>). Moreover, diagnostic tests for latent tuberculosis infection (ie, Mantoux test and in-vitro interferon gamma production) assess T-cell responses to mycobacterial antigens, responses that themselves might be affected by vitamin D status.</p></p></div><div class=page_fragment id=frag_5><div class="figTblUpiOuter svArticle" id=table_tbl2><div class=textboxdefault><dl class=table id=tbl2><dd class=lblCap><p class=caption><p><span class=label>Table 2. </span>Studies reporting serum 25-hydroxyvitamin D concentrations in patients with tuberculosis</p></p></dd><dd class=table><table><col><col><col><col><col><col><thead><tr><th colspan=1 rowspan=1></th><th colspan=1 rowspan=1><p><strong class=boldFont>Design</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Number of patients</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>25(OH)D cutoff</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>25(OH)D lower in active tuberculosis</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Findings</strong></th></p></tr></thead><tbody><tr><td colspan=1 rowspan=1><p>Davies, UK, 1985<span id=bbib116><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib116 id=ancbbib116><sup>116</sup></a></span><span id=btbl2fn1><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1 id=ancbtbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Case-control study of patients with tuberculosis and ethnically matched (related or unrelated) controls</td></p><td colspan=1 rowspan=1><p>50 cases; 50 controls</td></p><td colspan=1 rowspan=1><p>Not stated</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>Median 25(OH)D substantially lower in patients with tuberculosis than in controls (16·0 <em>vs</em> 27·2 nmol/L)</td></p></tr><tr><td colspan=1 rowspan=1><p>Grange et al, Indonesia, 1985 <span id=bbib117><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib117 id=ancbbib117><sup>117</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study in patients with smear-positive pulmonary tuberculosis and controls</td></p><td colspan=1 rowspan=1><p>40 cases; 38 controls</td></p><td colspan=1 rowspan=1><p>Not stated</td></p><td colspan=1 rowspan=1><p>No</td></p><td colspan=1 rowspan=1><p>Similar bimodal distribution of 25(OH)D in patients with tuberculosis and controls, with similar median values (65·6 nmol/L <em>vs</em> 69·4 nmol/L)</td></p></tr><tr><td colspan=1 rowspan=1><p>Davies et al, Kenya, 1987<span id=bbib118><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib118 id=ancbbib118><sup>118</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Case-control study of patients with tuberculosis and related controls</td></p><td colspan=1 rowspan=1><p>15 cases; 15 controls</td></p><td colspan=1 rowspan=1><p>Not stated</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>Median 25(OH)D substantially lower in patients with tuberculosis than in controls (39·7 <em>vs</em> 65·4 nmol/L); median 1,25D similar in cases and controls</td></p></tr><tr><td colspan=1 rowspan=1><p>Davies et al, Thailand, 1988<span id=bbib119><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib119 id=ancbbib119><sup>119</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Case-control study of patients with tuberculosis and healthy (blood donor) controls</td></p><td colspan=1 rowspan=1><p>51 cases; 51 controls</td></p><td colspan=1 rowspan=1><p>Not stated</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>Mean 25(OH)D substantially lower in patients with tuberculosis cases than in controls (24·5 <em>vs</em> 29·3 nmol/L)</td></p></tr><tr><td colspan=1 rowspan=1><p>Chan et al, Hong Kong, 1994<span id=bbib120><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib120 id=ancbbib120><sup>120</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Case-control study of patients with tuberculosis and controls receiving treatment for non-tuberculosis conditions</td></p><td colspan=1 rowspan=1><p>22 cases; 23 controls</td></p><td colspan=1 rowspan=1><p>Not stated</td></p><td colspan=1 rowspan=1><p>Yes, but difference not statistically significant</td></p><td colspan=1 rowspan=1><p>No substantial difference between patients with tuberculosis and controls in either 25(OH)D (46·4 <em>vs</em> 52·2 nmol/L, respectively) or 1,25D (45·9 <em>vs</em> 45·9 nmol/L, respectively)</td></p></tr><tr><td colspan=1 rowspan=1><p>Wilkinson et al, UK, 2000<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib76><sup>76</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Case-control study of patients with tuberculosis and tuberculosis contacts in people of Indian nationality</td></p><td colspan=1 rowspan=1><p>103 cases; 42 contacts</td></p><td colspan=1 rowspan=1><p>Deficient &lt;10 nmol/L</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>25(OH)D low in both groups; median 25(OH)D substantially lower in patients with tuberculosis than in contacts (12 <em>vs</em> 17 nmol/L), and undetectable 25(OH)D more common in patients with tuberculosis than in contacts (20/103=19% <em>vs</em> 1/42=2%)</td></p></tr><tr><td colspan=1 rowspan=1><p>Sasidharan et al, India, 2002<span id=bbib121><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib121 id=ancbbib121><sup>121</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study in patients with tuberculosis and controls</td></p><td colspan=1 rowspan=1><p>35 cases; 16 controls</td></p><td colspan=1 rowspan=1><p>Deficient &lt;22.5 nmol/L</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>Substantially lower mean 25(OH)D in patients with tuberculosis than in controls (26·7 <em>vs</em> 48·7 nmol/L); 16/35 tuberculosis cases and 0/16 controls with 25(OH)D &lt;22·5 nmol/L</td></p></tr><tr><td colspan=1 rowspan=1><p>Wejse et al, Guinea-Bissau, 2007<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib58 id=ancbbib58><sup>58</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study in patients with tuberculosis and unmatched healthy controls</td></p><td colspan=1 rowspan=1><p>362 cases; 494 controls</td></p><td colspan=1 rowspan=1><p>Insufficient (51–75 nmol/L); moderately deficient (26–50); severely deficient (≤25 nmol/L)</td></p><td colspan=1 rowspan=1><p>Yes, but deficiency more common in controls</td></p><td colspan=1 rowspan=1><p>Median 25(OH)D substantially lower in patients with tuberculosis than in controls (77·5 <em>vs</em> 83·0 nmol/L); moderate to severe deficiency (≤50 nmol/L) more common in healthy controls than in patients with tuberculosis (65/494=13·2% <em>vs</em> 31/362=8·6%)</td></p></tr><tr><td colspan=1 rowspan=1><p>Sita-Lumsden et al, UK, 2007<span id=bbib122><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib122 id=ancbbib122><sup>122</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional case-control study of children and adults; controls were matched for age, sex, and skin colour</td></p><td colspan=1 rowspan=1><p>178 cases; 130 controls</td></p><td colspan=1 rowspan=1><p>Deficient:&lt;21 nmol/L</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>25(OH)D substantially lower in patients with tuberculosis than in healthy controls (20·1 <em>vs</em> 30·8 nmol/L); more patients with tuberculosis in the deficient category (64% <em>vs</em> 31%); seasonal variation in 25(OH)D in controls, but not in patients with tuberculosis</td></p></tr><tr><td colspan=1 rowspan=1><p>Gibney et al, Australia, 2008<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib34><sup>34</sup></a></span></td></p><td colspan=1 rowspan=1><p>Retrospective</td></p><td colspan=1 rowspan=1><p>40 cases or past tuberculosis; 81 latent tuberculosis</td></p><td colspan=1 rowspan=1><p>Moderately to severely deficient &lt;25 nmol/L</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>25(OH)D lower in patients with latent tuberculosis than in patients with no tuberculosis (37·3 <em>vs</em> 54·6 nmol/L); 25(OH)D lower in patients with current (17·1 nmol/L) or past (13·3 nmol/L) tuberculosis than in patients with latent tuberculosis (37·3 nmol/L)</td></p></tr><tr><td colspan=1 rowspan=1><p>Friis, Tanzania, 2008<span id=bbib123><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib123 id=ancbbib123><sup>123</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study of patients with suspected tuberculosis</td></p><td colspan=1 rowspan=1><p>506 culture-positive tuberculosis; 129 culture-negative tuberculosis</td></p><td colspan=1 rowspan=1><p>Insufficient (50–75 nmol/L); mildly deficient (25–49); severely deficient (&lt;25 nmol/L)</td></p><td colspan=1 rowspan=1><p>Marginally lower in culture-positive tuberculosis than in culture-negative tuberculosis</td></p><td colspan=1 rowspan=1><p>Mean 25(OH)D sufficient, but lower in patients with culture-positive tuberculosis than in patients with culture-negative tuberculosis (85·5 <em>vs</em> 92·9 nmol/L)</td></p></tr><tr><td colspan=1 rowspan=1><p>Tostman et al, Tanzania, 2010<span id=bbib124><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib124 id=ancbbib124><sup>124</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span></td></p><td colspan=1 rowspan=1><p>Prospective study of 25(OH)D levels in patients with tuberculosis at diagnosis and 2-month follow-up</td></p><td colspan=1 rowspan=1><p>81 cases</td></p><td colspan=1 rowspan=1><p>Insufficient (50–75 nmol/L); deficient (&lt;50 nmol/L)</td></p><td colspan=1 rowspan=1><p>No comparison group</td></p><td colspan=1 rowspan=1><p>Sufficient 25(OH)D in most patients (67/81=83%), both at diagnosis and at 2-month follow-up; small but substantial rise in median 25(OH)D (from 24·0–101·0 nmol/L) at follow-up despite no supplementation</td></p></tr><tr><td colspan=1 rowspan=1><p>Nielsen et al, Greenland, 2010<span id=bbib125><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib125 id=ancbbib125><sup>125</sup></a></span></td></p><td colspan=1 rowspan=1><p>Matched case-control study</td></p><td colspan=1 rowspan=1><p>72 cases; 72 controls</td></p><td colspan=1 rowspan=1><p>Insufficient (50–75 nmol/L); mildly deficient (25–49 nmol/L); severely deficient (&lt;25 nmol/L)</td></p><td colspan=1 rowspan=1><p>Yes, but also in higher group</td></p><td colspan=1 rowspan=1><p>Both high (>140 nmol/L) and low (&lt;49 nmol/L) 25(OH)D associated with patients with tuberculosis cases, creating a U-shaped curve; serum for 25(OH)D collected either at diagnosis of tuberculosis or during treatment</td></p></tr><tr><td colspan=1 rowspan=1><p>Banda et al, Malawi, 2011<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib59 id=ancbbib59><sup>59</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study of patients with tuberculosis (82% HIV-positive)</td></p><td colspan=1 rowspan=1><p>161 cases</td></p><td colspan=1 rowspan=1><p>Deficient &lt;75 nmol/L</td></p><td colspan=1 rowspan=1><p>No comparison group</td></p><td colspan=1 rowspan=1><p>Deficient 25(OH)D in most patients (120/161=74·5%); 25(OH)D &lt;25 nmol/L in 21 patients (13%)</td></p></tr><tr><td colspan=1 rowspan=1><p>Nansera et al, Uganda, 2011<span id=bbib126><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib126 id=ancbbib126><sup>126</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span><span id=btbl2fn2><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn2 id=ancbtbl2fn2><sup>†</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study in patients with HIV, tuberculosis–HIV and controls (none with tuberculosis alone)</td></p><td colspan=1 rowspan=1><p>50 tuberculosis–HIV; 50 HIV; 50 controls</td></p><td colspan=1 rowspan=1><p>Deficient &lt;30 nmol/L</td></p><td colspan=1 rowspan=1><p>No, but deficiency more common in tuberculosis–HIV than in controls</td></p><td colspan=1 rowspan=1><p>No difference in mean 25(OH)D between controls, HIV and patients with tuberculosis–HIV; more patients with tuberculosis–HIV had 25(OH)D &lt;30 nmol/L (38% <em>vs</em> 20%) or &lt;12 nmol/L (12% <em>vs</em> 0%) than controls</td></p></tr><tr><td colspan=1 rowspan=1><p>Talat et al, Pakistan, 2000<span id=bbib127><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib127 id=ancbbib127><sup>127</sup></a></span></td></p><td colspan=1 rowspan=1><p>Prospective study of household tuberculosis contacts</td></p><td colspan=1 rowspan=1><p>100 household contacts; 28 current or past tuberculosis</td></p><td colspan=1 rowspan=1><p>Insufficient (45–67 nmol/L); deficient (&lt;45 nmol/L)</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>Median 25(OH)D low overall; similar in patients with tuberculosis and contacts (19·7 <em>vs</em> 24·0 nmol/L), but significantly lower when tuberculosis, past tuberculosis, and treated tuberculosis were grouped together <em>vs</em> contacts; 8/92 household contacts followed for 4 years developed tuberculosis, seven in the lowest, one in the middle, and none in the higher tertile of 25(OH)D; relative risk of progression to tuberculosis in lowest 25(OH)D group=5·1</td></p></tr><tr><td colspan=1 rowspan=1><p>Martineau, UK, 2011<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib29><sup>29</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn1><sup>*</sup></a></span><span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2fn2><sup>†</sup></a></span></td></p><td colspan=1 rowspan=1><p>Randomised controlled trial of vitamin D in tuberculosis including baseline measurement of 25(OH)D</td></p><td colspan=1 rowspan=1><p>126 cases</td></p><td colspan=1 rowspan=1><p>Profoundly deficient &lt;20 nmol/L</td></p><td colspan=1 rowspan=1><p>No comparison group</td></p><td colspan=1 rowspan=1><p>Mean 25(OH)D in patients with tuberculosis at baseline about 21 nmol/L; majority of patients (75/126) &lt;20 nmol/L at baseline, and almost all (122/126) &lt;75 nmol/L</td></p></tr><tr><td colspan=1 rowspan=1><p>Martineau et al, South Africa, 2011<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib101><sup>101</sup></a></span></td></p><td colspan=1 rowspan=1><p>Cross-sectional study of HIV-positive and HIV-negative adults with active or latent tuberculosis</td></p><td colspan=1 rowspan=1><p>192 cases; 178 latent tuberculosis</td></p><td colspan=1 rowspan=1><p>Deficient &lt;50 nmol/L</td></p><td colspan=1 rowspan=1><p>Yes</td></p><td colspan=1 rowspan=1><p>In HIV-negative patients, deficient 25(OH)D more common in patients with active tuberculosis than in patients with latent tuberculosis (75% <em>vs</em> 37%); in HIV-positive subjects, deficient 25(OH)D more common in patients with active tuberculosis than in patients with latent tuberculosis (86% <em>vs</em> 52%)</td></p></tr></tbody></table></dd><dd><p class=legend><p>25(OH)D=25-hydroxyvitamin D. 1,25D=1,25-dihydroxyvitamin D.</p></p></dd><dd><dl class=tblFootnote id=tbl2fn1><dt><ul><li>Serum 25(OH)D measured before start of tuberculosis treatment.</dt></li></ul></dl><dl class=tblFootnote id=tbl2fn2><dt><p>†Liquid chromatography-tandem mass spectrometry method used to measure 25(OH)D.</dt></p></dl></dd></dl></div></div><p class="svArticle section" id=para620><p>Patients with tuberculosis have insufficient 25-hydroxyvitamin D concentrations that are lower than in comparator populations (<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2>table 2</a></span>). A meta-analysis of seven international studies showed that low 25-hydroxyvitamin D levels were associated with high active tuberculosis risk.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib31><sup>31</sup></a></span> In a study from Greenland,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib125><sup>125</sup></a></span> where consumption of sea mammal liver, similar to cod-liver oil use, can produce high serum 25-hydroxyvitamin D concentrations, an unexpected U-shaped curve was identified, with both higher and lower 25-hydroxyvitamin D concentrations recorded in patients with tuberculosis compared with controls. High concentrations of potentially immunosuppressive omega-3 fatty acids and vitamin A in liver were suggested to explain this association,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib125><sup>125</sup></a></span> although Vieth&rsquo;s hypothesis,<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib70><sup>70</sup></a></span> or harm from high 25-hydroxyvitamin D concentrations, might be important considerations too.</p></p><p class="svArticle section" id=para630><p>We identified only one prospective study that provides evidence for the importance of vitamin D deficiency as an antecedent to development of active tuberculosis.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib127><sup>127</sup></a></span> In this study, household contacts of tuberculosis patients in Pakistan (who did not receive preventive treatment) were followed up for up to 4 years. The risk of progression to active tuberculosis was substantially higher (relative risk 5·1) among patients with the lowest 25-hydroxyvitamin D concentrations (<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl2>table 2</a></span>).</p></p><p class="svArticle section" id=para640><p>The main hypothesis to explain low vitamin D status in people with active tuberculosis is that a fall in serum 25-hydroxyvitamin D concentration precedes the diagnosis of tuberculosis, since this fall allows latent disease to become activated, as suggested by studies of migrants moving from high to low ultraviolet exposure settings.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib76>76</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib128 id=bbib128>128</a></sup> However, other hypotheses merit consideration (<span id=bbox2><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#box2 id=ancbbox2>panel 2</a></span>).</p></p><div class=textboxdefault id=box2><div><div class=textboxCaption><p><span class=textboxHead>Panel 2. </span><span class=caption>Hypotheses to explain the association between serum 25-hydroxyvitamin D and tuberculosis</span></div></p><div class=textboxBody><dl class=listitem id=list_celist50><dt class=label><p>•Vitamin D deficiency increases the risk of tuberculosis after exposure.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib26>26</a>, <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib27>27</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib34>34</a></sup></dt></p><dt class=label><p>•Vitamin D deficiency contributes to progression from latent to active tuberculosis.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib127><sup>127</sup></a></span></dt></p><dt class=label><p>•Vitamin D deficiency is a consequence of active tuberculosis due to low exposure to ultraviolet radiation and low dietary vitamin D, supported by the finding of spontaneous improvement in serum <a class=wiki href=25(OH)D rel>25(OH)D</a> during tuberculosis treatment in some instances.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib124>124</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib129 id=bbib129>129</a></sup></dt></p><dt class=label><p>•25-hydroxyvitamin D is low in patients with active tuberculosis owing to the effect of inflammatory processes on vitamin D metabolism. This hypothesis is supported by the finding that serum <a class=wiki href=25(OH)D rel>25(OH)D</a> can fall during development of tuberculosis immune restoration inflammatory syndrome, in inverse proportion to serum cytokines, suggesting that low <a class=wiki href=25(OH)D rel>25(OH)D</a> may be a consequence of immunological activation.<span id=bbib130><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib130 id=ancbbib130><sup>130</sup></a></span></dt></p><dt class=label><p>•Low 25-hydroxyvitamin D suggests a normal anti-tuberculosis immune response because upregulation of 1α-hydroxylase in activated macrophages causes available 25-hydroxyvitamin D to be converted to 1,25-dihydroxyvitamin D. In support of this hypothesis, 1,25-dihydroxyvitamin D provides negative feedback on 25-hydroxyvitamin D,<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib131 id=bbib131>131</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib132 id=bbib132>132</a></sup> and 1,25-dihydroxyvitamin D is raised in patients with tuberculosis compared with controls;<span id=bbib133><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib133 id=ancbbib133><sup>133</sup></a></span> note also 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D are related directly in tuberculosis patients but inversely in controls, suggesting changes in vitamin D metabolism in tuberculosis.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib120><sup>120</sup></a></span></dt></p><dt class=label><p>•Calcium deficiency in low-resource, tuberculosis-endemic settings contributes to raised serum 1,25-dihydroxyvitamin D and thus to low serum 25-hydroxyvitamin D.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib132 id=ancbbib132><sup>132</sup></a></span></dt></p><dt class=label><p>•Low serum cholesterol in under-nourished patients with tuberculosis contributes to low 25-hydroxyvitamin D concentrations in patients with active tuberculosis.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib41>41</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib134 id=bbib134>134</a></sup></dt></p><dt class=label><p>•If vitamin D assays are done after the start of anti-tuberculosis treatment, low 25-hydroxyvitamin D concentrations could be due to isoniazid or rifampicin.<sup><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib135 id=bbib135>135</a> and <a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib136 id=bbib136>136</a></sup></dt></p><dt class=label><p>•A factor common to both tuberculosis and low 25-hydroxyvitamin D—eg, vitamin D-binding protein might be lower at diagnosis of tuberculosis,<span id=bbib137><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib137 id=ancbbib137><sup>137</sup></a></span> its function could be changed and affect vitamin D binding,<span id=bbib138><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib138 id=ancbbib138><sup>138</sup></a></span> it can stimulate macrophages, and transports immunoactive molecules.<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib90><sup>90</sup></a></span></dt></p></dl></div></div></div></div><h2 class=svArticle id=cesec100><p>Clinical trials of vitamin D supplementation</h2></p><p class="svArticle section" id=para650><p>Although observational studies justify trials of vitamin D supplementation to inhibit progression from latent to active tuberculosis, such studies pose difficulties because they need large numbers of patients, long follow-up, and would need to show a clear additional benefit over evidence-based treatments for latent infection (eg, isoniazid preventive treatment and antiretroviral therapy for patients with HIV). Of note, vitamin D supplementation does not decrease the risk of tuberculosis in patients with renal dialysis.<span id=bbib139><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib139 id=ancbbib139><sup>139</sup></a></span></p></p><p class="svArticle section" id=para660><p>By contrast with the absence of prevention trials to date, administration of vitamin D in active disease has been reported over many decades. A review in 2006 of three trials and ten case series of treatment of patients with tuberculosis with vitamin D<span id=bbib140><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib140 id=ancbbib140><sup>140</sup></a></span> concluded that benefits were uncertain because the studies were of poor quality, often used vitamin D<sub>2</sub>, and did not examine the effect of vitamin D supplementation on outcomes. Subsequent trials show predominantly negative results (<span id=btbl3><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl3 id=ancbtbl3>table 3</a></span>). Such findings also characterise trials of vitamin D supplementation for other diseases. For example, despite a clear role for this vitamin in bone health, and vitamin D being commonly recommended for fracture prevention, most studies have failed to show an independent benefit of vitamin D in hip fracture prevention.<span id=bbib143><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib143 id=ancbbib143><sup>143</sup></a></span> Reasons that trials may fail to support findings from observational studies could include uncontrolled confounding; that vitamin D is indeed beneficial, but trials had inadequate power or used sub-optimal doses; that the 25-hydroxyvitamin D concentration examined in observational studies is a proxy for sun exposure and physical activity; or that host determinants, such as expression of 1α-hydroxylase and vitamin D binding protein, affect results. Furthermore, increases in serum 25-hydroxyvitamin D through vitamin D supplementation might not result in increased 1,25-hydroxyvitamin D to the neccessary concentrations or in the appropriate cellular compartments. Lappe and Heaney<span id=bbib144><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib144 id=ancbbib144><sup>144</sup></a></span> describe potential reasons for false-negative findings from vitamin D trials, including that the dose–response curve for vitamin D is sigmoid, so only a few patients towards the centre of the curve will experience substantial effects from a given supplementary dose. Recent results suggest more promising effects of vitamin D supplementation in tuberculosis than had previously been shown (<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#tbl3>table 3</a></span>).<span id=bbib142><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib142 id=ancbbib142><sup>142</sup></a></span></p></p><div class="figTblUpiOuter svArticle" id=table_tbl3><div class=textboxdefault><dl class=table id=tbl3><dd class=lblCap><p class=caption><p><span class=label>Table 3. </span>Clinical trials of vitamin D supplementation in adults with pulmonary tuberculosis, 2006–11</p></p></dd><dd class=table><table><col><col><col><col><col><col><thead><tr><th colspan=1 rowspan=1></th><th colspan=1 rowspan=1><p><strong class=boldFont>Design</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Number of patients</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Intervention</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Primary outcomes</strong></th></p><th colspan=1 rowspan=1><p><strong class=boldFont>Findings and comments</strong></th></p></tr></thead><tbody><tr><td colspan=1 rowspan=1><p>Nursyam et al, Indonesia, 2006<span id=bbib141><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib141 id=ancbbib141><sup>141</sup></a></span></td></p><td colspan=1 rowspan=1><p>Placebo controlled (unclear whether randomised)</td></p><td colspan=1 rowspan=1><p>Intervention (34); placebo (33)</td></p><td colspan=1 rowspan=1><p>10 000 IU (0·25 mg/day) vitamin D (D2 or D3 not stated) orally for 6 weeks</td></p><td colspan=1 rowspan=1><p>Clearance of acid-fast bacilli from sputum and chest radiograph improvement at 6 weeks</td></p><td colspan=1 rowspan=1><p>Substantial benefit from vitamin D, but methodological problems noted (mode of tuberculosis diagnosis and randomisation and masking processes not described)</td></p></tr><tr><td colspan=1 rowspan=1><p>Wejse et al, Guinea-Bissau, 2009<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib129 id=ancbbib129><sup>129</sup></a></span></td></p><td colspan=1 rowspan=1><p>Randomised, double blind, placebo controlled</td></p><td colspan=1 rowspan=1><p>Intervention (187); placebo (180)</td></p><td colspan=1 rowspan=1><p>100 000 IU cholecalciferol by injection at 0, 5, and 8 months</td></p><td colspan=1 rowspan=1><p>Composite clinical score at 2-monthly time points and 12-month mortality</td></p><td colspan=1 rowspan=1><p>No substantial benefit from vitamin D, but the dose was low (similar serum 25-hydroxyvitamin D at 2 and 8 months in both study groups); non-significant reduction in 1-month smear positivity in the vitamin D group; 60% of planned sample recruited</td></p></tr><tr><td colspan=1 rowspan=1><p>Martineau et al, UK, 2011<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib29><sup>29</sup></a></span></td></p><td colspan=1 rowspan=1><p>Randomised, double blind, placebo controlled</td></p><td colspan=1 rowspan=1><p>Intervention (62); placebo (64)</td></p><td colspan=1 rowspan=1><p>100 000 IU cholecalciferol orally at 0, 2, 4, and 6 weeks</td></p><td colspan=1 rowspan=1><p>Time to culture negativity</td></p><td colspan=1 rowspan=1><p>No substantial benefit from vitamin D overall, but TaqI vitamin D receptor genotype status affected response: time to culture conversion was much faster in patients with TaqI tt genotype randomised to vitamin D <em>vs</em> placebo; further analyses from this study, restricted to 95 patients fulfilling criteria for per-protocol analysis, found substantially faster sputum smear conversion and immunological impacts from supplemental vitamin D<span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#bib142><sup>142</sup></a></span></td></p></tr></tbody></table></dd><dd class=menuButtonLinks><div class=btnHolder><p><a class=menuTitle href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#>Table options</a></div></p></dd></dl></div></div><h2 class=svArticle id=cesec110><p>Conclusions</h2></p><p class="svArticle section" id=para670><p>The interpretation of studies on vitamin D needs an appreciation of assay variability and the controversies surrounding appropriate serum 25-hydroxyvitamin D reference ranges. Vitamin D has both immunosuppressive and immunostimulatory effects, and ultraviolet radiation, an important confounder, has mainly immunosuppressive effects. Whereas historical literature on phototherapy supports the use of vitamin D in patients with tuberculosis, direct mycobactericidal actions of exposure to ultraviolet light could have contributed to such findings, if indeed real benefits occurred. Low serum 25-hydroxyvitamin D concentrations could reflect an appropriate immune response of activated macrophages to <em>M tuberculosis</em>, because this molecule is consumed in the production of 1,25-hydroxyvitamin D, a mediator of important antimycobacterial effects. Because low baseline serum 25-hydroxyvitamin D in tuberculosis increases spontaneously over time, there is clearly a need for improved understanding of vitamin D metabolism in acute disease, especially disease characterised by macrophage activation, and in which protein synthesis, including vitamin D binding protein, could be impaired. The main trials of vitamin D in people with active tuberculosis to date have not been able to show major benefits overall.</p></p><p class="svArticle section" id=para680><p>The classification of the relation between vitamin D and tuberculosis risk through prospective surveillance of populations with latent infection or a clinical trial of supplementary vitamin D in this group, would need ambitious sample sizes. People at increased risk of developing active tuberculosis, such as HIV-positive individuals recently infected with tuberculosis, already need isoniazid preventive therapy with or without antiretrovirals; thus, benefits of vitamin D would need to be shown in addition to these optimised background treatment strategies. If HIV-negative individuals were selected, the sample size needed to detect a decrease in active tuberculosis rates from 5% to 3% during 2 years of follow-up, in people given placebo versus vitamin D, would be more than 4000. While such studies are not implausible, in the meanwhile, important scope exists for further investigation in patients with active tuberculosis to shed light on the vitamin D-tuberculosis association.</p></p><p class="svArticle section" id=para690><p>Research to address the hypotheses outlined in <span><a class=intra_ref href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#box2>panel 2</a></span> and to improve our understanding of vitamin D metabolism in active tuberculosis could include investigation of 25-hydroxyvitamin D concentration in relation to measured ultraviolet radiation exposure, 1,25-hydroxyvitamin D, parathyroid hormone, vitamin D binding protein, and VDR polymorphisms, at tuberculosis diagnosis and during recovery. Further supplementary trials in patients with active tuberculosis, which could incorporate these assessments, would best be done in vitamin D-deficient populations or subgroups selected on the basis of VDR polymorphisms, using adequate vitamin D doses that remain to be identified. Accessible, safe, and inexpensive measures to reduce the population burden of tuberculosis would be welcomed. Any major therapeutic role for vitamin D in tuberculosis remains an unproven but tantalising concept.</p></p><h2 class=svArticle id=cesec120><p>Search strategy and selection criteria</h2></p><div class=textboxdefault id=cetextbox10><div><div class=textboxBody><p class="svArticle section" id=para710><p>We searched PubMed for articles published in English from 1913 to Nov 2012, using the search terms “tuberculosis”, “vitamin D”, and “ultraviolet radiation”. We sourced further articles from our personal databases, and from references cited in papers identified through the process above.</p></p></div></div></div><div class=textboxdefault id=cetextbox20><div><div class=textboxBody><p class="svArticle section" id=para790><p><strong class=boldFont>This online publication has been corrected. The corrected version first appeared at thelancet.com/infection on January 21, 2013, and February 18, 2013</strong></p></p></div></div></div><p class="svArticle section" id=para720><p><strong class=boldFont>Contributors</strong></p></p><p class="svArticle section" id=para730><p>The authors made equal contributions to the literature searching and writing of the Review. Lead authors on separate components of the paper were APR for tuberculosis, RML for vitamin D, and MN for ultraviolet radiation.</p></p><p class="svArticle section" id=para740><p><strong class=boldFont>Conflicts of interest</strong></p></p><p class="svArticle section" id=para750><p>We declare that we have no conflicts of interest.</p></p><div class="articleText svArticle"><div class=articleText_indent><h2 class="h2 secHeading" id=ack001><p>Acknowledgements</h2></p><p class="svArticle section" id=para760><p><strong class=boldFont>Acknowledgments</strong></p></p><p class="svArticle section" id=para770><p>APR is supported by National Health and Medical Research Council (Australia)<a href=http://www.sciencedirect.com/science/article/pii/S147330991270275X#GS1>Fellowship 1016567</a> and a Sydney Medical Foundation grant to the Sydney Institute for Emerging Infections and Biosecurity. RML is supported by a National Health and Medical Research Council Career Development Fellowship.</p></p></div></div><p></p></div><hr class=tag-separator><div class=tags><span>Tags: </span><a href=/tags/antibiotics.html><span class=tag>antibiotics</span></a>
<a href=/tags/autoimmune.html><span class=tag>autoimmune</span></a>
<a href=/tags/bacteria.html><span class=tag>bacteria</span></a>
<a href=/tags/blood-levels.html><span class=tag>blood levels</span></a>
<a href=/tags/bone.html><span class=tag>bone</span></a>
<a href=/tags/bone-cancer.html><span class=tag>bone cancer</span></a>
<a href=/tags/cancer.html><span class=tag>cancer</span></a>
<a href=/tags/cancer-in-vdr.html><span class=tag>cancer in VDR</span></a>
<a href=/tags/child.html><span class=tag>child</span></a>
<a href=/tags/childhood-cancer.html><span class=tag>childhood cancer</span></a>
<a href=/tags/childhood-viruses.html><span class=tag>childhood viruses</span></a>
<a href=/tags/cholesterol.html><span class=tag>cholesterol</span></a>
<a href=/tags/cypr.html><span class=tag>CYPR</span></a>
<a href=/tags/dermatology.html><span class=tag>dermatology</span></a>
<a href=/tags/dialysis.html><span class=tag>dialysis</span></a>
<a href=/tags/dosage.html><span class=tag>dosage</span></a>
<a href=/tags/falls-fractures.html><span class=tag>falls fractures</span></a>
<a href=/tags/genetics.html><span class=tag>genetics</span></a>
<a href=/tags/health-risk.html><span class=tag>health risk</span></a>
<a href=/tags/high-dose.html><span class=tag>high dose</span></a>
<a href=/tags/hip-fractures.html><span class=tag>hip fractures</span></a>
<a href=/tags/immunity.html><span class=tag>immunity</span></a>
<a href=/tags/intervention.html><span class=tag>intervention</span></a>
<a href=/tags/kidney.html><span class=tag>kidney</span></a>
<a href=/tags/life-span.html><span class=tag>life span</span></a>
<a href=/tags/lupus.html><span class=tag>lupus</span></a>
<a href=/tags/mortality.html><span class=tag>mortality</span></a>
<a href=/tags/multiple-sclerosis.html><span class=tag>multiple sclerosis</span></a>
<a href=/tags/omega-3.html><span class=tag>omega 3</span></a>
<a href=/tags/omega-3-and-viruses.html><span class=tag>omega 3 and viruses</span></a>
<a href=/tags/pediatric-autoimmune.html><span class=tag>pediatric autoimmune</span></a>
<a href=/tags/pollution.html><span class=tag>pollution</span></a>
<a href=/tags/psoriasis.html><span class=tag>psoriasis</span></a>
<a href=/tags/rickets.html><span class=tag>rickets</span></a>
<a href=/tags/skin-cancer.html><span class=tag>skin cancer</span></a>
<a href=/tags/therapeutic-intervention.html><span class=tag>therapeutic intervention</span></a>
<a href=/tags/tuberculosis.html><span class=tag>tuberculosis</span></a>
<a href=/tags/tuberculosis.html><span class=tag>Tuberculosis</span></a>
<a href=/tags/ultraviolet-light.html><span class=tag>ultraviolet light</span></a>
<a href=/tags/virus.html><span class=tag>virus</span></a>
<a href=/tags/viruses-and-vitamin-d-receptor.html><span class=tag>viruses and vitamin d receptor</span></a>
<a href=/tags/vitamin-d.html><span class=tag>vitamin d</span></a>
<a href=/tags/vitamin-d-and-viruses.html><span class=tag>vitamin d and viruses</span></a>
<a href=/tags/vitamin-d-binding.html><span class=tag>vitamin d binding</span></a>
<a href=/tags/vitamin-d-blood-test.html><span class=tag>vitamin d blood test</span></a>
<a href=/tags/vitamin-d-receptor.html><span class=tag>vitamin d receptor</span></a></div><div data-pagefind-meta=tags hidden>antibiotics, autoimmune, bacteria, blood levels, bone, bone cancer, cancer, cancer in VDR, child, childhood cancer, childhood viruses, cholesterol, CYPR, dermatology, dialysis, dosage, falls fractures, genetics, health risk, high dose, hip fractures, immunity, intervention, kidney, life span, lupus, mortality, multiple sclerosis, omega 3, omega 3 and viruses, pediatric autoimmune, pollution, psoriasis, rickets, skin cancer, therapeutic intervention, tuberculosis, Tuberculosis, ultraviolet light, virus, viruses and vitamin d receptor, vitamin d, vitamin d and viruses, vitamin d binding, vitamin d blood test, vitamin d receptor</div><div class=scroll-nav-bottom id=article-bottom><a href=javascript:void(0); id=scroll-to-top class=scroll-button aria-label="Scroll to top" onclick='return window.scrollTo({top:0,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 12a.5.5.0 00.5-.5V5.707l2.146 2.147a.5.5.0 00.708-.708l-3-3a.5.5.0 00-.708.0l-3 3a.5.5.0 10.708.708L7.5 5.707V11.5a.5.5.0 00.5.5z"/></svg>
<span>Back to Top</span></a></div></article></div></div><script src="/js/toc-sanitizer.js?v=1753303882"></script><script src="/js/tiki-redirects.js?v=1753303882"></script><script src="/js/lightspa.js?v=1753303882"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1753303882",indexUrl:"/search/search_index.json.gz?v=1753303882"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/scroll-buttons.js?v=1753303882"></script></body></html>